Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer.

被引:2
|
作者
Abdou, Yara
Friend, Sarah Cooke
Patt, Yehuda Z.
Gan, Christine
Lee, Fa-Chyi
机构
[1] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
关键词
D O I
10.1200/JCO.2017.35.15_suppl.e15781
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e15781
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer
    Lee, F.
    Roach, M.
    Duong, L.
    Heywood, G.
    Parasher, G.
    Rasila, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
    Font, A
    Esteban, E
    Carles, J
    Climent, MA
    Gonzalez-Larriba, JL
    Berrocal, A
    Bellmunt, J
    Garcia-Ribas, I
    Marfa, X
    Fabregat, X
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 392S - 392S
  • [3] Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer.
    Burtness, B
    Sipples, R
    Mirto, G
    Thomas, L
    Ahman, ZA
    Kloss, RA
    Murren, J
    Lacy, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 342S - 342S
  • [4] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer.
    Song, Eun-Kee
    Han, Hye-Suk
    Lee, Ki Hyeong
    Lee, Kyu Taek
    Bae, Sang Byung
    Kim, Han Jo
    Kim, Samyong
    Yun, Hwan Jung
    Cho, Sang Hoe
    Shim, Hyun-Jeong
    Yhim, Ho-Young
    Leo, Na-Ri
    Joon, So Yoon
    Yim, Chang-Yeoi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] CETUXIMAB IN COMBINATION WITH CAPECITABINE, IRINOTECAN, AND RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER: RESULTS OF A PHASE II MARGIT TRIAL
    Horisberger, Karoline
    Treschl, Anne
    Mai, Sabine
    Barreto-Miranda, Manuel
    Kienle, Peter
    Stroebel, Philipp
    Erben, Philipp
    Woernle, Christoph
    Dinter, Dietmar
    Kaehler, Georg
    Hochhaus, Andreas
    Post, Stefan
    Willeke, Frank
    Wenz, Frederik
    Hofheinz, Ralf-Dieter
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (05): : 1487 - 1493
  • [7] Oxaliplatin and Irinotecan in advanced gastric cancer.: A multicenter phase II trial
    Woell, E.
    Eisterer, W.
    Hilbe, W.
    Kuehr, T.
    Gattringer, K.
    Greil, R.
    Zabernigg, A.
    Baldinger, C.
    Thaler, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 213 - 213
  • [8] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [9] Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
    Carles, J.
    Esteban, E.
    Climent, M.
    Font, A.
    Gonzalez-Larriba, J. L.
    Berrocal, A.
    Garcia-Ribas, I.
    Marfa, X.
    Fabregat, X.
    Albanell, J.
    Bellmunt, J.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (08) : 1359 - 1362
  • [10] Gemcitabine and oxaliplatin combination:: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
    Carles, Joan
    Esteban, E.
    Climent, M.
    Font, A.
    Gonzalez-Larriba, J. L.
    Berrocal, A.
    Fabregat, X.
    Albanell, J.
    Bellmunt, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 151 - 152